CLAIMS

What is claimed is:

1. Use of a therapeutically effective amount of at least one herbal composition selected from the group consisting of:

(a) an herbal extract YIV-906 comprising herbal extracts of *Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z),* a fraction thereof, or any active chemical present in the herbal extract or the fraction thereof, and

(b) β-glucuronidase treated YIV-906 (YIV-906GU) or a fraction thereof, or any active chemical present in the YIV-906GU or the fraction thereof;

in the manufacture of a medicament for use in combinatorial therapy for treating and/or preventing recurrence of a cancer in a mammal, wherein the medicament is to be administered to the mammal in combination with an effective amount of at least one immunotherapeutic agent.

2. The use of claim 1, wherein the cancer comprises a solid tumor.

3. The use of any one of claims 1-2, wherein the cancer is at least one selected from the group consisting of melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and pancreatic cancer.

4. The use of any one of claims 1-3, wherein the at least one immunotherapeutic agent is an immune checkpoint inhibitor selected from the group consisting of an anti-PD1, an anti-PD-L1, and an anti-CTLA4 inhibitor.

5. The use of any one of claims 1-4, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of Ipilimumab, Pembrolizumab, Nivolumab, Durvalumab, and Atezolizumab.

6. The use of any one of claims 1-5, wherein the at least one immunotherapeutic agent is an antibody selected from the group consisting of siglec 15 antibody, anti-phosphatidylserine, anti-OX40, anti-CD73, anti-TIM3, anti-CD24, anti-CD47, anti-PD1, anti-PDL1, anti-

CTLA4, anti-GITR, anti-CD27, anti-CD28, anti-CD122, anti-TIGIT, anti-VISTA, anti-ICOS, and anti-LAG3.

7. The use of any one of claims 1-6, wherein the herbal composition enhances response of the at least one immunotherapeutic agent.

8. The use of any one of claims 1-7, wherein the medicament is to be administered to the mammal orally.

9. The use of any one of claims 1-8, wherein the medicament promotes stimulator of interferon genes (STING) agonist action.

10. The use of any one of claims 1-9, wherein the medicament is to be administered to the mammal orally in a form selected from the group consisting of a pill, tablet, capsule, soup, tea, concentrate, dragees, liquids, drops, and gelcaps.

11. The use of any one of claims 1-10, wherein the therapeutically effective amount of the herbal composition is about 20 mg/day to about 2000 mg/day.

12. The use of any one of claims 1-11, wherein the therapeutically effective amount of the herbal composition is about 1600 mg/day.

13. The use of any one of claims 1-12, wherein the medicament is to be administered twice daily.

14. The use of any one of claims 1-12, wherein the medicament is to be administered for about one to about two weeks, followed by a suspension of treatment for at least one week.

15. The use of any one of claims 1-14, wherein the medicament is to be administered about 30 mins before a chemotherapy or a radiation therapy is to be administered.

16. The use of claim 15, wherein the medicament is to be administered continuously for about 4 days.

17. The use of any one of claims 1-16, wherein the medicament is to be administered at a time selected from prior to, simultaneously with, and after administration of the one or more immunotherapeutic agent to the mammal.

18. The use of any one of claims 1-17, wherein the mammal is a human.